NCT06222164 The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
| NCT ID | NCT06222164 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Invivoscribe, Inc. |
| Condition | Hematologic Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2024-03-30 |
| Primary Completion | 2027-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2024-03-30 with a primary completion date of 2027-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research
Eligibility Criteria
Inclusion Criteria: 1. Specimen/sample, peripheral blood (PB), bone marrow (BM), genomic DNA (gDNA) and/or formalin-fixed paraffin-embedded tissue (FFPE) from patients whose specimens/samples have been sent to LabPMM for clinical testing 2. Donor Age ≥ 18 years Exclusion Criteria: 1. Sample/specimen has been obtained from a third-party vendor with a Materials Transfer Agreement (MTA) on file with LabPMM 2. The specimens/samples have previously been enrolled in a clinical study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06222164 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hematologic Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06222164 currently recruiting?
Yes, NCT06222164 is actively recruiting participants. Contact the research team at aschut@invivoscribe.com for enrollment information.
Where is the NCT06222164 trial being conducted?
This trial is being conducted at San Diego, United States.
Who is sponsoring the NCT06222164 clinical trial?
NCT06222164 is sponsored by Invivoscribe, Inc.. The trial plans to enroll 2,000 participants.